CerSci Therapeutics Inc Information
Contact top employees from
CerSci Therapeutics Inc
Summary
CerSci Therapeutics Inc is a private company that has been in the industry for 10 years. The company currently specializes in the Biotechnology, Pharmaceuticals areas. The position of the Co-Founder & CEO is occupied by Lucas Rodriguez. Its headquarters is located at Dallas, Texas, USA. The number of employees ranges from 25 to 100. The annual revenue of CerSci Therapeutics Inc varies between 5.0M and 25M. Total funding of the company - $12M. To connect with CerSci Therapeutics Inc employee register on SignalHire.
Industries
Biotechnology
Headquarters Location
Employees Size
1-10 employees
Specialties
Research, Chemistry, Pharmaceuticals, Development
SIC Code
2834
DMA Code
Dallas-fort Worth Metropolitan Area
Founded
2015
Estimated Annual Revenue
$5.0M - 25M
Operating Status
Subsidiary
Competitors
Founded | Type | Employees | Revenue | Funding | |
|---|---|---|---|---|---|
| 2019 | Public Company | 25 - 100 | < 1M | $52.5M | |
| 2004 | Public Company | 25 - 100 | 123.3M | $98M | |
| 1983 | Public Company | 100 - 250 | 83M | $174M | |
| 2017 | Privately Held | 1-10 | - | $- | |
| 2013 | - | 10-50 | - | $- | |
| 2013 | - | 1-10 | - | $- |
Employees Turnover 3 quarter 2025
Length of Employment
Employee tenure at CerSci Therapeutics Inc shows a diverse range of experience levels:
63% for 5–7 years38% for 8–10 yearsContact top employees from
CerSci Therapeutics Inc
Similar Companies
FAQ
CerSci Therapeutics Inc operates in the Biotechnology industries. More details can be found on the official website: CerSci.com.
The headquarters of CerSci Therapeutics Inc are located in Dallas, United States.
The current CEO of CerSci Therapeutics Inc is Lucas Rodriguez
You can contact CerSci Therapeutics Inc by phone at 214-306-6218.
CerSci Therapeutics Inc currently employs 1-10 people.
CerSci Therapeutics Inc's revenue is approximately 10M.
Well-known competitors of CerSci Therapeutics Inc include Baudax Bio, Cara Therapeutics, Heron Therapeutics, Inc. and Sollis.
